These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. An overview of treatment of overactive bladder syndrome in women. Allahdin S; Oo N J Obstet Gynaecol; 2012 Apr; 32(3):217-21. PubMed ID: 22369391 [TBL] [Abstract][Full Text] [Related]
4. Overactive bladder: treatment options in primary care medicine. Sussman DO J Am Osteopath Assoc; 2007 Sep; 107(9):379-85. PubMed ID: 17908830 [TBL] [Abstract][Full Text] [Related]
5. Validity and reliability of the patient's perception of intensity of urgency scale in overactive bladder. Cartwright R; Srikrishna S; Cardozo L; Robinson D BJU Int; 2011 May; 107(10):1612-7. PubMed ID: 21070569 [TBL] [Abstract][Full Text] [Related]
6. Etiology and treatment of overactive bladder in women. Shaw HA; Burrows LJ South Med J; 2011 Jan; 104(1):34-9. PubMed ID: 21079535 [TBL] [Abstract][Full Text] [Related]
7. Overactive bladder symptoms in women: current concepts in patient management. Easton WA Can J Urol; 2010 Feb; 17 Suppl 1():12-7. PubMed ID: 20170596 [TBL] [Abstract][Full Text] [Related]
8. Medical management of overactive bladder. Radomski SB; Barkin J Can J Urol; 2012 Oct; 19 Suppl 1():2-9. PubMed ID: 23089342 [TBL] [Abstract][Full Text] [Related]
9. Frequently asked questions in the evaluation and management of overactive bladder. Ellsworth PI; Brunton SA; Wein AJ; Rovner ES J Fam Pract; 2009 Oct; 58(10 Suppl):S1-11; quiz S12. PubMed ID: 19874737 [No Abstract] [Full Text] [Related]
10. Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health-related quality of life in patients with overactive bladder treated with tolterodine. Coyne KS; Elinoff V; Gordon DA; Deng DY; Brodsky M; Glasser DB; Jumadilova Z; Carlsson M Int J Clin Pract; 2008 Jun; 62(6):925-31. PubMed ID: 18479285 [TBL] [Abstract][Full Text] [Related]
11. Psychometric validation of the overactive bladder satisfaction with treatment questionnaire (OAB-SAT-q). Margolis MK; Fox KM; Cerulli A; Ariely R; Kahler KH; Coyne KS Neurourol Urodyn; 2009; 28(5):416-22. PubMed ID: 19030182 [TBL] [Abstract][Full Text] [Related]
13. New evidence in the treatment of overactive bladder. Brown ET; Martin L; Dmochowski RR Curr Opin Obstet Gynecol; 2015 Oct; 27(5):366-72. PubMed ID: 26308197 [TBL] [Abstract][Full Text] [Related]
17. Re: Overactive bladder: a better understanding of pathophysiology, diagnosis and management. A. J. Wein and R. R. Rackley J Urol, suppl., 2006; 175: S5-S10. Löfgren OE J Urol; 2007 Oct; 178(4 Pt 1):1553; author reply 1553. PubMed ID: 17707052 [No Abstract] [Full Text] [Related]
18. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study. Sand P; Zinner N; Newman D; Lucente V; Dmochowski R; Kelleher C; Dahl NV BJU Int; 2007 Apr; 99(4):836-44. PubMed ID: 17187655 [TBL] [Abstract][Full Text] [Related]
19. The overactive bladder syndrome: treating patients on an individual basis. Cardozo L BJU Int; 2007 Jun; 99 Suppl 3():1-7. PubMed ID: 17488366 [No Abstract] [Full Text] [Related]
20. A review of cost-effectiveness comparisons for overactive bladder treatments: which is the most cost-effective for improving quality of life? Giannitsas K; Athanasopoulos A Expert Rev Pharmacoecon Outcomes Res; 2015 Jun; 15(3):413-23. PubMed ID: 25656409 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]